MSLN and pleural neoplasm: Mayor et al. and Adusumilli et al. demonstrated that intrapleural injection of anti-mesothelin (MSLN) CD28 costimulatory (M28z) CAR-T cells effectively eliminated established pleural tumors, even at doses 30 times lower than those required for intravenous injection.